Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock

Key Points

• Chief Accounting Officer Donald Zakrowski sold 2,000 Eli Lilly shares for approximately $2.37 million at an average price of $1,185.01. The transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving him with 1,526 shares.
• Eli Lilly shares fell 1.5% to $1,212.96, near the company’s 52-week high, despite strong quarterly results. Earnings of $8.38 per share and revenue of $22.97 billion exceeded estimates, with revenue up 47.7% year over year.
• The company declared a quarterly dividend of $1.73 per share, equivalent to an annualized $6.92 and a 0.6% yield. Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $1,292.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Stock Down 1.5%

NYSE LLY traded down $18.98 during trading on Tuesday, hitting $1,212.96. The company's stock had a trading volume of 2,087,659 shares, compared to its average volume of 3,136,508. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market cap of $1.14 trillion, a PE ratio of 40.70, a P/E/G ratio of 1.38 and a beta of 0.51. The business's 50 day simple moving average is $1,162.38 and its 200-day simple moving average is $1,048.95. Eli Lilly and Company has a fifty-two week low of $629.40 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first regulatory approval outside the United States and gives Lilly access to a major European market. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The approval expands Lilly’s obesity portfolio beyond injectable medicines and could improve patient convenience and market adoption. Foundayo will initially be available through private prescriptions, while potential access through Britain’s National Health Service depends on a cost-effectiveness review. Lilly Takes Its Weight-Loss Pill Battle Overseas
• Positive Sentiment: Investor sentiment remains supported by Lilly’s strong recent results: quarterly revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Management raised fiscal 2026 EPS guidance to $35.50–$36.50, marking another outlook increase. Eli Lilly Beat Big and Raised Guidance
• Neutral Sentiment: Analysts have lifted some valuation targets, with one updated fair-value estimate rising to $1,297.31. However, the stock is trading near its 52-week high and at roughly 41 times earnings, leaving less room for disappointment. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its fiscal 2026 EPS estimate to $34.93 from $35.34. Although the revised forecast remains close to Lilly’s guidance, the cut contrasts with the broader bullish outlook. Eli Lilly analyst estimate
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The scheduled nature of the transaction makes it a limited bearish signal, but it may add some selling pressure. SEC Form 4 Filing

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research note on Thursday, June 25th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Rothschild & Co Redburn raised their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 18th. Finally, Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,292.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $30,000. Maseco LLP grew its stake in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. increased its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares in the last quarter. Finally, Aventus Investment Advisors Inc. increased its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after acquiring an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source